All In Biotech

Drug Trial Radar · NCT01148849

Safety Study of MGAH22 in HER2-positive Carcinomas

A Phase 1, Dose Escalation Study of MGAH22 in Patients With Refractory HER2 Positive Breast Cancer and Patients With Other HER2 Positive Carcinomas for Whom No Standard Therapy Is Available

Last checked: Nov 20, 2026Latest source record: Feb 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

66

Actual

Start

Jul 2010

Primary completion

Jun 14, 2022

Study completion Jun 14, 2022

Sponsor

Lead sponsor
MacroGenicsIndustry
Sponsor type
Industry
Collaborators
Green Cross Corporation; National Cancer Institute (NCI)
First posted
Jun 22, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if MGAH22 is safe when given by intravenous (IV) infusion to patients with HER2-positive cancer. The study will also evaluate how long MGAH22 stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it has an effect on tumors.

Conditions

  • Breast Cancer
  • Gastric Cancer

Interventions

  • margetuximabBiological

    margetuximab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Adverse Events and Serious Adverse EventsTime frame: Up to 28 days after last infusion

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • National Cancer Institute

    Bethesda, Maryland

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Seoul National University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.